Featured Research

from universities, journals, and other organizations

5-alpha-reductase Inhibitors And Reduced Prostate Cancer Risk: A Mixed Set Of Results

Date:
April 15, 2008
Source:
Wiley-Blackwell
Summary:
Compared to placebo treatment, taking 5-alpha-reductase inhibitors (5-ARIs) can reduce a man's risk of being diagnosed with prostate cancer from around 5--9 percent to around 4-6 percent during up to 7 years of treatment, according to a new Cochrane Review.

Compared to placebo treatment, taking 5-alpha-reductase inhibitors (5-ARIs) can reduce a man's risk of being diagnosed with prostate cancer from around 5--9% to around 4-6% during up to 7 years of treatment, according to a new Cochrane Review. However, those who are diagnosed with prostate cancer may be at a slightly increased risk of having a more dangerous (high grade) tumour. Additionally, the vast majority of cancers detected in these studies were very small and unlikely to cause any clinical problems during a man's lifetime.

Related Articles


Prostate cancer affects around 220,000 men each year in the USA alone, killing about 27,000 of them. Men over the age of 65 are at greatest risk. Safe and effective methods to prevent prostate cancer would be beneficial.

The hormone testosterone is one of the factors that may encourage these tumours to grow. There is now a range of 5-alpha-reductase inhibitors that disrupt the biochemical pathway that generates testosterone, therefore potentially reducing the incidence of prostate cancer development.

A group of Cochrane Researchers searched existing literature for trials that looked at the effects of these drugs in men. They found good and bad results.

On the positive side, the drugs led to slight decreases in the incidence of prostate cancer and can improve common benign lower urinary tract symptoms such as hesitancy, straining, frequency and night time urination.

On the negative side, when cancer was detected it was more likely to be of a high grade in men receiving 5 alpha reductase inhibitors. The reason for this is uncertain, and could be because the drugs alter the way that the tumour cells grow. However, it could be that these drugs just alter the way the cells look under the microscope rather than affecting their clinical prognosis. In addition there was evidence with one 5-ARI (finasteride) that it has a tendency to impair sexual or erectile function.

"There is a lot we still don't know and future research must determine whether 5-ARIs reduce the overall risk of dying from prostate cancer, whether any of the different 5-ARIs on the market does a better job than the others and whether the potential benefits outweigh the risks," says lead researcher Dr Timothy Wilt, Coordinating Editor of the Cochrane Prostatic Disease and Urologic Cancers group based at Veterans Affairs Medical Centre in Minneapolis, Minnesota, USA.


Story Source:

The above story is based on materials provided by Wiley-Blackwell. Note: Materials may be edited for content and length.


Cite This Page:

Wiley-Blackwell. "5-alpha-reductase Inhibitors And Reduced Prostate Cancer Risk: A Mixed Set Of Results." ScienceDaily. ScienceDaily, 15 April 2008. <www.sciencedaily.com/releases/2008/04/080415194358.htm>.
Wiley-Blackwell. (2008, April 15). 5-alpha-reductase Inhibitors And Reduced Prostate Cancer Risk: A Mixed Set Of Results. ScienceDaily. Retrieved October 24, 2014 from www.sciencedaily.com/releases/2008/04/080415194358.htm
Wiley-Blackwell. "5-alpha-reductase Inhibitors And Reduced Prostate Cancer Risk: A Mixed Set Of Results." ScienceDaily. www.sciencedaily.com/releases/2008/04/080415194358.htm (accessed October 24, 2014).

Share This



More Health & Medicine News

Friday, October 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Breakfast Debate: To Eat Or Not To Eat?

Breakfast Debate: To Eat Or Not To Eat?

Newsy (Oct. 23, 2014) Conflicting studies published in the same week re-ignited the debate over whether we should be eating breakfast. Video provided by Newsy
Powered by NewsLook.com
Ebola Fears Keep Guinea Hospitals Empty

Ebola Fears Keep Guinea Hospitals Empty

AP (Oct. 23, 2014) Fears of Ebola are keeping doctors and patients alike away from hospitals in the West African nation of Guinea. (Oct. 23) Video provided by AP
Powered by NewsLook.com
Despite Rising Death Toll, Many Survive Ebola

Despite Rising Death Toll, Many Survive Ebola

AP (Oct. 23, 2014) The family of a Dallas nurse infected with Ebola in the US says doctors can no longer detect the virus in her. Despite the mounting death toll in West Africa, there are survivors there too. (Oct. 23) Video provided by AP
Powered by NewsLook.com
Orthodontist Mom Jennifer Salzer on the Best Time for Braces

Orthodontist Mom Jennifer Salzer on the Best Time for Braces

Working Mother (Oct. 22, 2014) Is your child ready? Video provided by Working Mother
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins